Dezvoltarea de noi antivirale cu molecule mici pentru patogeni cu potențial epidemic

Orizont Europa

Pe scurt

Banii sunt pentru cercetare și inovație care să ducă la noi terapeutice antivirale cu molecule mici împotriva unor viruși cu potențial epidemic sau pandemic, cum ar fi arenavirusurile, virusurile encefalitei sau enterovirusul D68. Finanțarea acoperă descoperirea și optimizarea candidaților antivirali, testarea in vitro și in vivo, producția conform GMP și primele studii clinice de siguranță la om. Se pot aplica entități din țările eligibile Orizont Europa, iar participarea start-up-urilor și a IMM-urilor este încurajată.

Grant per proiect

9.000.000 la 11.000.000 EUR

Buget total apel

44.200.000 EUR

Se deschide

29.10.2026

Tip de acțiune

HORIZON Research and Innovation Actions

Eligibilitate România

Organizațiile din România pot aplica

Identificator apel

HORIZON-HLTH-2027-01-DISEASE-05

Sursă

Portalul UE pentru finanțări (apeluri tematice)

Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:The scientific and clinical communities have a better understanding of and access to experimental antivirals for the prevention and treatment of emerging or re-emerging viral infections, as well as for further clinical investigation.Candidate antiviral therapies are available to treat patients for emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic. Scope:Infectious diseases remain a major threat to health and health security in the EU and globally. Viral disease emergence is already being accelerated by climate change, and thus a proactive approach to the development of antiviral prophylactics and therapeutics in preparedness for future infectious disease outbreaks is needed. The availability of antivirals targeting conserved viral or host mechanisms would provide a critical preparedness measure against future health threats caused by (re)emerging infectious disease epidemics or pandemics, due to infectious disease epidemics or pandemics.This topic contributes to strengthening the Research and Innovation ecosystem within the EU and supports the implementation of the European Medical Countermeasures Strategy[1].Antibodies and antibody derived proteins are excluded from the scope of this topic.Applicants should explicitly state in their proposal which of the following viruses/groups of viruses is targeted and the proposed work should address only this specific virus/group of viruses. The proposed work should aim to advance the development of novel or existing antiviral candidates targeting exclusively one of the following viruses/groups of viruses: Junin mammarenavirus and/or Lassa mammarenavirusTick-borne encephalitis virus and/or Japanese encephalitis virusAndes virus and/or Hantaan virus and/or Sin Nombre virusHendra virusEnterovirus D68Venezuelan equine encephalitis virus Identifying a specific virus/group of viruses does not preclude the exploration of these antiviral candidates' effects on other viruses/groups of viruses. Proposals should thus aim to diversify and accelerate the global prophylactic and therapeutic research and development portfolio for emerging and re-emerging viral infections, and to strengthen the leading role of the EU in prophylactic and therapeutic research and development.Proposals should address some of the following research areas:Discovery and selection of candidate antivirals with consideration for intra-family and/or variant-transcending potential.Optimisation of selected candidates to improve potency, selectivity, pharmacokinetics, and developability, using Structure-Activity Relationship (SAR) studies or equivalent methodologies.In-vitro characterisation of antiviral activity, mechanism of action, and, where appropriate, resistance potential across multiple viruses or strains.In-vivo tests in at least one animal model or, if available in human organoid or organotypic models, to demonstrate the protective function of the antiviral candidates and deemed sufficient for moving to first clinical trials.If requested by regulators as pre-requisite for clinical studies, in-vivo tests in a non-human primate model.Production of batches of the most promising antiviral candidates according to the Good Manufacturing Practices (GMP)[2] of the most promising therapeutics solution.First in human clinical safety studies demonstrating a clear regulatory pathway for market authorisation. Attention should be paid to critical biological and social factors such as sex, age, ethnicity and disability. Participation of third countries where viruses addressed in the proposal are endemic or where outbreaks have occurred or are ongoing is encouraged.The participation of start-ups, micro, small and medium-sized enterprises (SMEs)[3] is encouraged with the aim of strengthening their scientific and technological foundations, enhancing their innovation potential, and exploring possibilities for commercial exploitation.All projects funded under this topic are expected to engage with regulatory bodies in a timely manner to ensure adequacy of the actions from a regulatory point of view.Proposals should advance research by leveraging already existing and emerging state-of-the-art research infrastructures[4] such as those having contributed to the services developed under the ISIDORe project[5].The projects funded under this topic should synergise with projects funded by the co-funded European Partnership for Pandemic Preparedness[6].Applicants should provide details of their clinical studies[7] in the dedicated annex using the template provided in the submission system. As proposals under this topic are expected to include clinical studies, the use of the template is strongly encouraged.[1] https://health.ec.europa.eu/health-emergency-preparedness-and-response-hera/preparedness/medical-countermeasures-strategy_en[2] https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en[3] https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32003H0361[4] The catalogue of European Strategy Forum on Research Infrastructures (ESFRI) research infrastructures portfolio can be browsed on the ESFRI website: https://ri-portfolio.esfri.eu[5] https://isidore-project.eu[6] https://cordis.europa.eu/project/id/101226682, https://beready4pandemics.eu[7] Please note that the definition of clinical studies (see introduction to this Work Programme part) is broad and it is recommended that you review it thoroughly before submitting your application.

General conditions1. Admissibility Conditions, proposal page limit and layoutAdmissibility conditions are described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.Proposal page limits and layout are described in Part B of the Application Form available in the Submission System.2. Eligible CountriesEligible countries are described in Annex B of the Work Programme General Annexes.A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.3. Other Eligibility ConditionsIn recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).Other eligibility conditions are described in Annex B of the Work Programme General Annexes.4. Financial and operational capacity and exclusionFinancial and operational capacity and exclusion are described in Annex C of the Work Programme General Annexes.5a. Evaluation and award: Award criteria, scoring and thresholdsTo ensure a balanced project portfolio covering the viruses/groups of viruses targeted in this topic[[Virus/group of viruses i to vi, as given in the scope of this topic.]], grants will be awarded (within available budget) to proposals not only in order of ranking but at least also to those proposals that are the highest ranked within different viruses/groups of viruses targeted, provided that the proposals attain all thresholds.Award criteria, scoring and thresholds are described in Annex D of the Work Programme General Annexes.5b. Evaluation and award: Submission and evaluation processesThe thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold will be 12.Submission and evaluation processes are described in Annex F of the Work Programme General Annexes and the Online Manual.5c. Evaluation and award: Indicative timeline for evaluation and grant agreementIndicative timeline for evaluation and grant agreement are described in Annex F of the Work Programme General Annexes.6. Legal and financial set-up of the grantsThe granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5.Legal and financial set-up of the grants are described in Annex G of the Work Programme General Annexes.Specific conditions Specific conditions are described in the specific topic of the Work Programme. Application and evaluation forms and additional documents: Application and evaluation form templatesStandard application form (HE RIA, IA) - the application form specific to this call is available in the Submission SystemStandard evaluation form (HE RIA, IA) - will be used with the necessary adaptationsGuidanceHE Programme GuideModel Grant Agreement (MGA)HE MGACall-specific instructions Information on clinical studies (HE)Additional documents HE Main Work Programme 2026-2027-1. General IntroductionHE Main Work Programme 2026-2027-4. HealthHE Main Work Programme 2026-2027-15. General AnnexesHE Programme GuideHE Framework Programme 2021/695HE Specific Programme Decision 2021/764EU Financial Regulation 2024/2509Decision authorising the use of lump sum contributions under the Horizon Europe ProgrammeRules for Legal Entity Validation, LEAR Appointment and Financial Capacity AssessmentEU Grants AGA, Annotated Model Grant AgreementFunding & Tenders Portal Online ManualFunding & Tenders Portal Terms and ConditionsFunding & Tenders Portal Privacy Statement

Apelul oficial

Condițiile din ghidul oficial sunt singurele care contează la depunere.

Program